0
Skip to Content
B+ | Fighting Childhood Cancer B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
B+ | Fighting Childhood Cancer B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Folder: ABOUT
Folder: GET INVOLVED
Folder: RESEARCH
Folder: NEED HELP?
BLOG
MERCH
DONATE
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
The Netherlands, International Julia Travagline 12/16/24 The Netherlands, International Julia Travagline 12/16/24

Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Dr. Max M. van Noesel, MD. PhD, MSc; – Princess Máxima Center, Utrecht, The Netherlands

Read More
Comprehensive molecular profiling of pediatric adrenal tumors
The Netherlands, International Julia Travagline 12/16/24 The Netherlands, International Julia Travagline 12/16/24

Comprehensive molecular profiling of pediatric adrenal tumors

Comprehensive molecular profiling of pediatric adrenal tumors

Dr. Ronald de Krijger – Princess Máxima Center, Utrecht, The Netherlands

Read More
Pulmonary complications in children with solid tumors
International, The Netherlands Julia Travagline 12/16/24 International, The Netherlands Julia Travagline 12/16/24

Pulmonary complications in children with solid tumors

Pulmonary complications in children with solid tumors

Dr. S.M.P.J. Prevaes; Dr. M. van Grotel – Princess Máxima Center, Utrecht, The Netherlands

Read More
Factsheet
International, The Netherlands Julia Travagline 12/16/24 International, The Netherlands Julia Travagline 12/16/24

Factsheet

Factsheet

Dr. Geert O. Janssens; Dr. Matteo Maspero; Dr. Marry M. van den Heuvel-Eibrink  – Princess Máxima Center, Utrecht, The Netherlands

Read More
Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma

Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma

Dr. Jiao Zhang, Ph.D. – Baylor College of Medicine, Houston TX

Read More
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Northeast, Connecticut Julia Travagline 11/20/24 Northeast, Connecticut Julia Travagline 11/20/24

Uncovering the role of chromosome 21 in Down syndrome-associated leukemias

Uncovering the role of chromosome 21 in Down syndrome-associated leukemias

Dr. Jason Sheltzer, Ph.D. – Yale University, New Haven, CT

Read More
Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma
Northeast, Maryland Julia Travagline 11/20/24 Northeast, Maryland Julia Travagline 11/20/24

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Dr. Rosa Nguyen, M.D., Ph.D. – National Cancer Institute, NIH NCI Pediatric Oncology, Bethesda, MD

Read More
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
West, Oregon Julia Travagline 11/20/24 West, Oregon Julia Travagline 11/20/24

Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia

Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia

Dr. Julia Maxson, Ph.D. – Oregon Health & Science University – OHSU, Portland, OR

Read More
Therapeutic downregulation of core circuitry genes in mutant MYOD1 rhabdomyosarcoma
Midwest, Ohio Julia Travagline 11/20/24 Midwest, Ohio Julia Travagline 11/20/24

Therapeutic downregulation of core circuitry genes in mutant MYOD1 rhabdomyosarcoma

Therapeutic downregulation of core circuitry genes in mutant MYOD1 rhabdomyosarcoma

Dr. Berkley Gryder, Ph.D. – Case Western Reserve University School of Medicine, Cleveland, OH

Read More
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Midwest, Missouri Julia Travagline 11/20/24 Midwest, Missouri Julia Travagline 11/20/24

Cooperative mutagenesis driving pediatric pre-B cell leukemia

Cooperative mutagenesis driving pediatric pre-B cell leukemia

Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO

Read More
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy

Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy

Dr. Ketan Ghaghada, Ph.D. – Baylor College of Medicine, Houston TX

Read More
HBEGF as a novel therapeutic target for Diffuse Midline Glioma
Northeast, New York Julia Travagline 11/20/24 Northeast, New York Julia Travagline 11/20/24

HBEGF as a novel therapeutic target for Diffuse Midline Glioma

HBEGF as a novel therapeutic target for Diffuse Midline Glioma

Dr. Oren Becher, M.D. – Icahn School of Medicine at Mount Sinai, New York, NY

Read More
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX

Read More
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
New York, Northeast Julia Travagline 11/20/24 New York, Northeast Julia Travagline 11/20/24

The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

Dr. lannis Aifantis, Ph.D. – New York University Grossman School of Medicine, New York, NY

Read More
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

CAR gamma delta T cell-based multi-pronged immunotherapy for AML

CAR gamma delta T cell-based multi-pronged immunotherapy for AML

Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine

Read More
Dietary valine modulation to enhance therapies for high-risk T-ALL
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Dietary valine modulation to enhance therapies for high-risk T-ALL

Dietary valine modulation to enhance therapies for high-risk T-ALL

Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX

Read More
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Northeast, Mas Julia Travagline 11/20/24 Northeast, Mas Julia Travagline 11/20/24

Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients

Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients

Dr. Kristopher Sarosiek, Ph.D. – President and Fellows of Harvard College, Harvard T. H. Chan School of Public Health, Boston, MA

Read More
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
South, Tennessee Julia Travagline 11/20/24 South, Tennessee Julia Travagline 11/20/24

A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

Dr. Hiroto Inaba, M.D. – St. Jude Children's Research Hospital, Inc., Memphis, TN

Read More
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Midwest, Michigan Julia Travagline 11/20/24 Midwest, Michigan Julia Travagline 11/20/24

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI

Read More
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Northeast, Washington D.C. Julia Travagline 11/20/24 Northeast, Washington D.C. Julia Travagline 11/20/24

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Dr. Yanxin Pei, M.D. – Children's Research Institute (CNMC), Washington, D.C.

Read More
Older Posts

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark